Selventa analyzes molecular patient data, accelerates the development process and clarifies decisions on therapeutics and diagnostics for pharmaceutical and biotechnology partners. As a personalized healthcare organization, the goal is to join strategic partners in finding optimal treatments for the right patients. Ultimately, the value proposition starts with patient stratification and associated biomarker panels, and results in the identification of underlying disease mechanisms for single and combination therapeutic interventions for a given disease.  Selventa is a Flagship VentureLabs company.

Noubar Afeyan is a Founder of the Company and Jim Matheson is Chairman of the Board.